Prashant Mehta
@Prasshmehta
Medical Oncologist-Lymphoma,Acute Lymphoblastic Leukemia ,CAR T-cell Rx,Indian CAR-T initiative, Haplo HSCT,trying my best to save lives with Medicine and Music
My first independent music album ‘Dil Besabraa’ goes live on all digital platforms on Dec 22,2021 All proceeds will fund treatment of cancer patients Do stream more and more if you like . Let me tell you few things about myself in this thread , read on 1/n
Excellent paper by @MirghSumeet et al Financial toxicity can be cut to 1% by replacing plerixafor with cyclophosphamide ± bortezomib And keeping the transplant outcomes similar! Practice changing, definitely! @nihardesai89 @Prasshmehta @NicoGagelmann
Just published in @CancerMedicine 15 years of PBSC mobilization experience in Myeloma Even in the CAR-T era, collecting sufficient PBSCs is crucial. - GCSF+plerixafor comparable to chemo mobilization - If prior RT (to hematopoietic sites - spine, pelvis), chemo-mobn is better
The Kind Warrior’s Way – A Perspective The Kind Warrior is not one who battles others, but one who trains within. He sharpens his sword not for war, but for self-mastery. He builds his strength not to dominate, but to protect joy, integrity, and peace. This way of living does…
Very insightful report @lingarajnayak
🔥 Cyclophosphamide (high dose) - for refractory ICANS post CAR-T from @TataMemorial @RahulBanerjeeMD @DrNikitaMehra @nihardesai89 @purwarrahul2 @RanjitKSMD @DrGauravNarula @Prasshmehta @SuyogCancer onlinelibrary.wiley.com/doi/10.1111/bj…
This is a major update Thank you dear Prof 🙏🏻
SQ blinatumomab is highly effective in R-R ALL with CR/CRh rate of 77%, MRD-negativity rate of 91%, and 12-month OS rate of 63-70%. The 250 µg/500 µg dose was selected as the recommended phase 2 dose. @MDAndersonNews #Leukemia doi.org/10.1016/s2352-… #leusm
Excellent summary of #ICML2025 for R/R DLBCL ‘Three regimens. Three new paths forward. All better than what rituximab plus GemOx could offer’ POLARGO- STARGLO-SUNMO and then the newer DLBCL Classifiers LymphoMAP particularly of interest in the context of CAR-T efficacy
Just published in @ASCOPost My reflections from ICML 2025 — where lymphoma history met its future. From COO giving way to molecular clusters, to the TME guiding CART outcomes, to the undeniable momentum in aggressive B-cell lymphoma 👉 ascopost.com/news/july-2025… #ICML2025 #lymsm
In REACH3, ruxolitinib vastly improved failure-free survival (38.4 vs 5.7 months) over best therapy in steroid-refractory chronic GVHD, with durable responses and no new safety issues over 3 years. @JCO_ASCO ascopubs.org/doi/10.1200/JC…
👉Here is an updated version of the Table which I initially posted post ASH2024. 👉Now Updated with EHA 2025 data including updated FLAIR, CLL13, CAPTIVATE trials. #CLL
Our deeper dive on @BMTCTN 1506 aka Morpho trial: FLT3-ITD/NPM1 co mutants with residual MRD uniquely benefit from #gilteratinib maintenance. FLT3-ITD/NPM1 co-mutation status may inform #alloHCT conditioning intensity decision #bmtsm #leusm ashpublications.org/bloodadvances/…
📢 Now available online ! Full article : Comparable response rates of venetoclax 50 mg with posaconazole versus venetoclax 400 mg despite lower pharmacokinetic exposure in newly diagnosed acute myeloid leukemia: less is enough 👉tandfonline.com/doi/full/10.10… #asco2025 poster,…
Big news indeed
Big news: Mosun-Pola is superior to chemotherapy for patients with aggressive lymphoma. At @icmlugano, I was honored to present—on behalf of an incredible team of global coauthors—the SUNMO trial: ➡️ First positive Phase III trial in this space without conventional chemotherapy
ICML25: Outpatient fixed duration Mosun-Pola regimen is highly efficacious in 3L+ R/R MCL in this phase 2 cohort: 71% had 3+ high risk features (prior CAR, ASCT, TP53, Blastoid/pleomorphic, Ki67 30%+ etc). ORR 88%, CR79% CRS all low grade and resolved.
UBC study of DA-R-EPOCH in DHL (implemented provincewide in 2015). Superior TTP & OS with EPOCH vs RCHOP era. No difference in survival based on MYC Ig partner. OS worse with EPOCH if DZsig+. #18ICML #lymsm
I favor the same There is no high quality data in support of IT or IV CNS prophylaxis
.@CwynKate rebuttal #18ICML: - Telling a story with the English football team: there is no high-quality data supporting prophy (IT or IV) - better detection of occult SCNSL is key (ctDNA) #lymsm 2/
One of the longest follow-up studies I've seen in DLBCL. Excess mortality from infection remains higher than general population for greater than 10 years. AML/MDS highest 1-4 yrs, lung & GI cancers 5-25 yrs. Cardiac deaths have fallen over time. #18ICML #lymsm
LEO/MER outcomes of sequential v concurrent transformed FL @DrCarlaCasulo #18ICML: inferior EFS and OS with sequential transformation, and worst survival if transformation within 2 years. #lymsm
thanks for sharing @majorajay
EBV+ pts in S1826 had much better PFS with nivo-AVD, although age & IPS differences between EBV+/- cohorts. Non-NS histologies also had much better PFS with nivo. #18ICML #lymsm
We are also interested in knowing and understanding this work more Let us know if we can participate in any way @dgermain21 @majorajay @Lymphoma_Doc
This work will be hugely important to help define a path forward for treating DLBCL: which patients are most likely to benefit from CAR T-cell, work to be done to understand if other therapies could overcome adverse biology. We are open to collaborate!
Pola bridging to CAR #18ICML - 200 pts: 122 polaBR, rest polaR - no diff in pre-CAR ORR with polaBR v polaR - more heme tox with BR - more ICANS w/ BR? tl;dr polaR just fine for bridging. #lymsm #tcellrx